CAMBRIDGE, Mass.--(BUSINESS WIRE)--HighPassBio, an ElevateBio portfolio company dedicated to advancing novel targeted T cell immunotherapies, today discussed the ongoing Phase 1 trial of the companys lead product candidate, an engineered T cell receptor (TCR) T cell therapy targeting HA-1 expressing cancer cells in an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting. The Phase 1 clinical trial, which is being conducted by researchers at Fred Hutchinson Cancer Research Center, is designed to assess the feasibility, safety, and efficacy of this novel cell therapy in the treatment of leukemia following hematopoietic stem cell transplant (HSCT).
The prognosis for leukemia patients whove relapsed or who have residual disease following allogeneic hematopoietic stem cell transplantation is often poor, but we believe that by targeting the minor H antigen, HA-1, through a novel T cell immunotherapy, we can potentially treat and prevent subsequent relapse, said Elizabeth Krakow, M.D., MSc., Assistant Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, principal investigator of the study, and presenting author. We have observed early promising indicators of anti-leukemic activity following treatment in this trial. We are eager to expand the trial to additional patients as we continue to research the feasibility, safety, and efficacy of this approach.
The abstract for the presentation titled Phase 1 Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for Children and Adults with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT): Trial in Progress, can be found on the ASH website under the abstract number 137726.
To date, four patients, including one pediatric patient, have received a total of six infusions in the Phase 1 clinical trial. Patient characteristic data was shared in the oral presentation at ASH, including documented HA-1 TCR T cell persistence in blood and bone marrow up to 18 months. In some patients, clear in vivo anti-leukemic activity was observed at the first dose level, including a subject with aggressive, highly refractory T-ALL and early post-HCT relapse. No significant toxicities attributed to the T cells have been observed, including no infusion reactions or evidence of cytokine release syndrome or graft versus host disease.
The Phase 1 clinical trial is currently recruiting adult and pediatric patients who have residual disease or relapsed leukemia or related conditions following HSCT. As part of the trial, transplant patients and prospective donors may be recruited to participate in the genetic screening portion to determine eligibility. More details are available on clinicaltrials.gov under the study ID number NCT03326921.
About TCR-Engineered T Cell Therapy
A key role of the immune system is to detect tumor antigens, engage T cells, and eradicate the tumor. However, the immune response to tumor antigens varies and is often insufficient to prevent tumor growth and relapse. An approach known as adoptive T cell therapy, using T cell receptors, or TCRs, can overcome some of the obstacles to establishing an effective immune response to fight off the target tumor. TCRs are molecules found on surface of T cells that can recognize tumor antigens that are degraded to small protein fragments inside tumor cells. Unlike CAR T cells that recognize only surface antigens, TCRs can recognize small protein fragments derived from intracellular and surface antigens offering a more diverse way to attack tumors. These small protein fragments show up on the tumor cell surface, with another protein called major histocompatibility complex (MHC), that are recognized by the TCRs and consequently signal the bodys immune system to respond to fight off and kill the tumor cells.
Tumor-specific TCRs can be identified and then engineered into T cells that recognize and attack various types of cancers, representing a novel approach to treating and potentially preventing disease.
Adoptive T cell therapy can be applied to tackling relapse of leukemia post hematopoietic stem cell transplant (HSCT) by targeting the antigens expressed only by the patients native cells, and not by the cells from the stem cell transplant donor. HA-1, a known minor histocompatibility antigen, is expressed predominantly or exclusively on hematopoietic cells, including leukemic cells. There is evidence that T cells specific for HA-1 can induce a potent and selective antileukemic effect. HA-1 TCR T cell therapy is a new investigational immunotherapy for the management of post transplantation leukemia relapse.
About Leukemia post HSCT Treatment and the Risk of Relapse
Leukemia, a cancer of the blood or bone marrow characterized by an abnormal proliferation of blood cells, is the tenth most common type of cancer in the U.S. with an estimated 60,140 new cases and 24,400 deaths in 2016. Leukemia arises from uncontrolled proliferation of a specific type of hematopoietic (blood) cell that is critical for a functional immune system. As a result, when patients are given very high doses of chemotherapy to eradicate leukemic cells, most normal cells are killed as well, necessitating a transplant of hematopoietic stem cells from a donor to reconstitute the patients bone marrow and circulating hematopoietic cells. In some cases, the transplanted T cells from the donor can also recognize and eliminate the hematopoietic cells, including leukemia, from the recipient, thus preventing relapse. This can be described as a graft versus leukemia effect. Other hematologic disorders related to leukemia, like myelodysplastic syndrome (MDS), can also be treated in this way.
While HSCT can be curative, it is estimated that 25-50 percent of HSCT recipients relapse; leukemia relapse remains the major cause of allogeneic HSCT failure, and the prognosis for patients with post-HCT relapse is poor. Relapse occurs following allogeneic HSCT in approximately one-third of patients with acute leukemia who undergo the procedure, and most patients subsequently die of their disease.
HighPassBio, an ElevateBio portfolio company, is working to advance a novel approach to treating hematological malignancies by leveraging T cell receptor (TCR)-engineered T cells, known as TCR T cells. The companys lead program is designed to treat or potentially prevent relapse of leukemia in patients who have undergone hematopoietic stem cell transplant (HSCT). The technology was born out of research conducted at Fred Hutchinson Cancer Research Center by world renowned expert, Dr. Marie Bleakley.
ElevateBio, LLC, is a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies. It begins with an environment where scientific inventors can transform their visions for cell and gene therapies into reality for patients with devastating and life-threatening diseases. Working with leading academic researchers, medical centers, and corporate partners, ElevateBios team of scientists, drug developers, and company builders are creating a portfolio of therapeutics companies that are changing the face of cell and gene therapy and regenerative medicine. Core to ElevateBios vision is BaseCamp, a centralized state-of-the-art innovation and manufacturing center, providing fully integrated capabilities, including basic and translational research, process development, clinical development, cGMP manufacturing, and regulatory affairs across multiple cell and gene therapy and regenerative medicine technology platforms. ElevateBio portfolio companies, as well as select strategic partners, are supported by ElevateBio BaseCamp in the advancement of novel cell and gene therapies.
ElevateBios investors include F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital, The Invus Group, Surveyor Capital (A Citadel company), EDBI, and Vertex Ventures.
ElevateBio is headquartered in Cambridge, Mass, with ElevateBio BaseCamp located in Waltham, Mass. For more information, please visit http://www.elevate.bio.
- Cell therapy strategies for COVID-19: Current approaches and potential applications - Science Advances - August 18th, 2021
- Stem Cell Therapy Market worth $40.3 billion by 2027 Exclusive Report by CoherentMarketInsights - PharmiWeb.com - August 18th, 2021
- Therapeutic Solutions International Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Compared to other... - August 18th, 2021
- Atf3 and Rab7b genes drive regeneration in mature cells - Baylor College of Medicine News - August 18th, 2021
- U of T's Medicine by Design helps unite international researchers working to map every human cell - News@UofT - August 18th, 2021
- Mesenchymal Stem Cells Market Witnesses Upward Trend with High Prevalence of Parkinson's Disease The Manomet Current - The Manomet Current - July 22nd, 2021
- BioRestorative Therapies Announces Notice of Allowance for a New Patent Application Related to its Off-the-Shelf ThermoStem Program -... - April 4th, 2021
- Transplant After CD19 CAR T-Cell Therapy Shows Durable Disease Control in Children, Young Adults With B-ALL - Cancer Network - April 4th, 2021
- Stem Cell Assay Market Changing Dynamics Of Competition With Forecast To 2030 The Bisouv Network - The Bisouv Network - April 4th, 2021
- Stem Cell Therapy Market Research Reveals Enhanced Growth During The Forecast Period 2017 2025 FLA News - FLA News - March 8th, 2021
- Adult Stem Cells Market Size, Share, Global Industry Overview, Challenges, Business Overview and Forecast Research Study 2024 (Effect of the COVID-19... - February 17th, 2021
- Be The Match encourages people of color to join bone marrow registry - KING5.com - February 17th, 2021
- Discovery for turning on cell repair in tissues and organs - Monash University - February 17th, 2021
- Manageable Safety Profile Observed in Phase 1 Studies Examining UCART19 for Pediatric and Adult Patients with B-Cell ALL - Cancer Network - February 11th, 2021
- The Very First Signs of an Immune Response Have Been Filmed in a Developing Embryo - ScienceAlert - February 11th, 2021
- JSP191 With Low Dose Irradiation and Fludarabine is Safe and Effective for Patients with MRD+ AML/MDS - Cancer Network - February 9th, 2021
- Creative Bioarray Offers Stem Cell Lines Generation Service for Promoting Scientific Research - Press Release - Digital Journal - February 9th, 2021
- JSP191 With Low Dose Irradiation and Chemotherpy Demonstrates Efficacy and Safety in MRD+ AML/MDS - Targeted Oncology - February 9th, 2021
- Stem Cells Market Value to Reach Around USD 17.79 Bn by 2027 - GlobeNewswire - February 4th, 2021
- Global Adult Stem Cells Market Revenue To Witness Humongous Elevation By 2026 Market Research Store Jumbo News - Jumbo News - February 4th, 2021
- Stem Cell Therapy Market to Score Past US$ 40.3 Billion Valuation by 2027: At a CAGR of 21.1% KSU | The Sentinel Newspaper - KSU | The Sentinel... - February 2nd, 2021
- Reduced Adult Neurogenesis Linked with Alzheimers Disease - The Scientist - February 2nd, 2021
- Regenerative Medicine (Bone and Joint) Market to Score Past US$ 14990.0 Million Valuation by 2027: CMI KSU | The Sentinel Newspaper - KSU | The... - February 2nd, 2021
- Orthopedic Regenerative Medicine Market Size to Witness A Lucrative Growth Over 2020-2027 | Curasan, Inc., Carmell Therapeutics Corporation, Anika... - February 2nd, 2021
- Adult Stem Cells Market Demand, Growth Challenges, Industry Analysis And Forecasts To 2026 | Epistem Ltd.,Globalstem,Mesoblast Ltd.,Brainstorm Cell... - February 2nd, 2021
- ToolGen ties up with 3D bioprinting company to apply induced pluripotent stem cells to gene correction - Aju Business Daily - February 2nd, 2021
- Medicine by Design researchers focus on promoting self-repair of the brain - News@UofT - January 31st, 2021
- Should You Buy Brainstorm Cell Therapeutics Inc (BCLI) Stock on Tuesday? - InvestorsObserver - January 31st, 2021
- Eye stem cell transplant to treat blindness bolsters retinal function in monkeys - FierceBiotech - January 14th, 2021
- Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine - Science Advances - January 14th, 2021
- RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing - GlobeNewswire - January 14th, 2021
- Reversing The Aging Clock With Epigenetic Reprogramming - Bio-IT World - January 14th, 2021
- New Models in Organoids Market Open New Vistas in Stem Cell Research for Cancer, Global Valuation to Reach US$ 12.8 Bn by 2030: TMR - PRNewswire - January 12th, 2021
- Health Canada Approves ONUREG (azacitidine tablets), First Maintenance Therapy for Patients in Remission from Acute Myeloid Leukemia - Canada NewsWire - January 12th, 2021
- Stem Cells Market 2020 Research Study including Growth Factors, Types and Application to 2026| Covid-19 Impact - Farming Sector - January 9th, 2021
- The real reason behind goosebumps - Jill Lopez - January 3rd, 2021
- Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity - Science Advances - January 3rd, 2021
- New Approaches to the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma - Targeted Oncology - January 3rd, 2021
- CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy Indications - Targeted Oncology - December 26th, 2020
- CRISPR and another genetic strategy fix cell defects in two common blood disorders - Science Magazine - December 6th, 2020
- Multiple sclerosis iPS-derived oligodendroglia conserve their properties to functionally interact with axons and glia in vivo - Science Advances - December 6th, 2020
- UCART22 Safe and Active in CD22-Expressing B-Cell ALLs - Targeted Oncology - December 6th, 2020
- Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) - Cheshire Media - December 6th, 2020
- Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 - The Haitian-Caribbean News Network - December 5th, 2020
- Stem Cell Assay to Register Substantial Expansion by 2026| Merck, Thermo Fisher Scientific, GE Healthcare - The Haitian-Caribbean News Network - December 5th, 2020
- Stem Cell Therapy Global Market Report 2020-30: Covid 19 Growth and Change - GlobeNewswire - November 25th, 2020
- Functionally distinct resident macrophage subsets differentially shape responses to infection in the bladder - Science Advances - November 25th, 2020
- BioRestorative Therapies Emerges from Chapter 11 Reorganization Other OTC:BRTX - GlobeNewswire - November 20th, 2020
- Jakafi and Dacogen May Improve Overall Survival in Patients with MPN - Curetoday.com - November 20th, 2020
- BRTX-100; the Story of BioRestorative Therapies Inc (OTCMKTS: BRTX) - MicroCap Daily - November 20th, 2020
- As California Passes Prop 14, What Is Stem Cell Research and Why Is It Controversial? - Newsweek - November 16th, 2020
- Organoids mimic the early development of the heart in mouse embryos - BioNews - November 16th, 2020
- Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection - DocWire News - November 16th, 2020
- Cynata Therapeutics (ASX:CYP) begins phase three osteoarthritis trial - The Market Herald - November 16th, 2020
- $ 30.1 billion Worth Cell Expansion Market, Led by Thermo Fisher Scientific Inc, Becton, Dickinson and Company, Terumo BCT and Others. re:Jerusalem -... - November 3rd, 2020
- Impact of COVID-19 on Advanced Wound Care Management Market : Implications on Business Strategies, Countermeasures, Economic Impact - The Think... - November 1st, 2020
- Stem Cells Market 2020 Is Growing with Highest Size, Share of Top Key Players in the Industry and Forecast Survey Till 2024 - Zenit News - October 30th, 2020
- Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease - DocWire News - October 30th, 2020
- JadiCell Stem Cells Licensed by Therapeutic Solutions International for Brain Injury Significantly Increased Survival of COVID-19 Patients in Double... - October 29th, 2020
- Impact Of Covid 19 On Adult Stem Cells Market 2020 Industry Challenges, Business Overview And Forecast Research Study 2026 - PRnews Leader - October 29th, 2020
- APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an Off-the-Shelf Allogeneic Stem Cell Product for the Treatment of... - October 29th, 2020
- Why Small Businesses Matter in Wilton (Reimagined): Interventional Orthopedics Connecticut - HamletHub - October 29th, 2020
- Covid-19 Impact On Orthopedic Regenerative Medicine Market 2020 Future Development, Manufacturers, Trends, Share, Size And Forecast to 2027 |... - October 29th, 2020
- Cell Expansion Market a comprehensive study by key players- Thermo Fisher Scientific, Inc, Becton, Dickinson and Company, Terumo BCT, Merck KGaA and... - October 24th, 2020
- Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma... - October 24th, 2020
- What Is the Role of Allogeneic-SCT in Adult Acute Lymphoblastic Leukemia in the Era of Targeted Therapies? - Targeted Oncology - October 21st, 2020
- Cell Therapy Market Size, Share, Market Research and Industry Forecast Report, 2020-2027 (Includes Business Impact of COVID-19) - Eurowire - October 17th, 2020
- Global Stem Cell Therapy Market (Covid-19 updated report), Trends, Top Manufacturers, Exponential Growth and Forecast 2020 to 2027 By Reportspedia -... - October 17th, 2020
- Was Trump's Regeneron 'Cure' Developed Using Stem Cells and Fetal Tissues? - Snopes.com - October 13th, 2020
- The complicated story of Trump's COVID treatment, stem cells and abortion politics - Baptist News Global - October 13th, 2020
- BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa - PRNewswire - October 13th, 2020
- Human heart organoids provide unmatched insight into cardiac disease and dysfunction - BioWorld Online - October 13th, 2020
- Sickle Cell Disease Association of America and Aruvant Sciences Forge New Partnership to Educate Around Gene Therapy - Herald-Mail Media - October 13th, 2020
- Q Stock; The Rise of BioRestorative Therapies Inc (OTCMKTS: BRTXQ) - MicroCap Daily - October 8th, 2020
- A Uniquely Patient-Focused Take on Treating AML in Older Adults - Medscape - October 8th, 2020
- Dust off the crystal ball: It's time for STAT's 2020 Nobel Prize predictions - STAT - October 3rd, 2020
- BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Corporate Upd - PharmiWeb.com - October 3rd, 2020
- Cell Harvesting Market to Witness Steady Expansion During 2018-2023 - The Market Records - October 1st, 2020
- Global Mesenchymal Stem Cells Market to Witness Exponential Rise in Revenue Share During the Forecast Period - Lake Shore Gazette - September 7th, 2020
- Keeping kids and adults alike healthy with Colostrum - North Coast Courier - September 4th, 2020